Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. (NASDAQ: AZTA) is a global leader in providing advanced life sciences solutions, empowering breakthrough therapies and expediting their market reach. Headquartered in Burlington, MA, Azenta operates across North America, Europe, and Asia, catering to top pharmaceutical, biotech, academic, and healthcare institutions worldwide.
Azenta offers a comprehensive array of reliable cold-chain sample management solutions and genomic services, spanning critical areas such as drug development, clinical research, and advanced cell therapies. The company’s core business is divided into two segments: Life Sciences Products and Life Sciences Services, with the latter being the primary revenue driver.
Recent achievements highlight Azenta's robust financial health and strategic initiatives. In the fourth quarter of fiscal 2023, the company delivered impressive results amidst challenging economic conditions, underscored by robust cost reduction programs and strategic investments in its sales force. This progress translates into a promising outlook for fiscal 2024, with expected organic revenue growth of 5 to 8%, continued margin expansion, and positive free cash flow.
Azenta's commitment to driving long-term shareholder value is evident through its planned $500 million share repurchase initiative for fiscal 2024. This underscores the company's strong balance sheet and ample liquidity, which includes approximately $500 million in available cash for strategic investments.
Key partnerships and expansions further solidify Azenta's industry footprint. The recent opening of a new Genomics Laboratory in Oxford, UK, enhances its reach, providing local researchers with advanced next-generation sequencing technologies and expertise. Additionally, Azenta has been selected by the Crohn's & Colitis Foundation to manage sample services for significant research cohorts, emphasizing its pivotal role in advancing precision medicine.
Azenta’s portfolio showcases industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems, which deliver essential support and innovation in life sciences research and development.
The company is also noted for its prudent use of non-GAAP financial measures, providing investors with a clear perspective on operational results relative to industry peers. These measures complement traditional GAAP results by adjusting for items like amortization of intangible assets and restructuring charges, offering a more comprehensive view of financial performance.
As Azenta continues to navigate its transformational journey, including a CEO succession plan aimed at sustaining growth and innovation, it remains committed to its mission of accelerating impactful therapies and supporting the global scientific community.
Azenta, Inc. (Nasdaq: AZTA) has rescheduled its second fiscal quarter earnings release for 2022 from May 3, 2022, to May 9, 2022, due to delays in the quarter-end closing process following the sale of its Semiconductor Automation business on February 1, 2022. The company anticipates that the second quarter revenue and non-GAAP EPS will remain within the previously issued guidance range. A conference call is scheduled for May 9, 2022, at 4:30 p.m. ET to discuss the financial results.
Azenta, Inc. (Nasdaq: AZTA) will announce its fiscal 2022 second quarter earnings on May 3, 2022, after market close. The results will cover the quarter ending March 31, 2022. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day, accessible via phone and live webcast. Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services to major pharmaceutical and biotech companies worldwide.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, featuring a presentation at 9:30 am ET. The event will be accessible via a live webcast on the Azenta investor relations website, with a replay available afterward. Azenta provides comprehensive life sciences solutions, focusing on cold-chain sample management and genomic services for pharmaceutical and biotech industries globally. The company rebranded from Brooks Automation to Azenta, Inc. on December 1 last year.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 22, 2022. The event will feature a presentation at 3:00 PM ET in a virtual format, accessible via Azenta's investor relations website.
Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services for drug development and clinical research. The company rebranded from Brooks Automation, Inc. on December 1.
Azenta, Inc. (Nasdaq: AZTA) will participate in the Barclays Global Healthcare Conference on March 15, 2022, with a presentation at 10:15am ET. The event takes place in Miami, FL, and a live webcast is available on Azenta's investor relations website. A replay will also be accessible post-event. Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services. The company rebranded from Brooks Automation on December 1, adopting the new name and ticker symbol.
Azenta, Inc. (Nasdaq: AZTA) will participate in Cowen's 42nd Annual Health Care Conference on March 8, 2022, with a live presentation at 2:10 PM ET. The conference will be held virtually, and interested parties can access the live webcast via the Azenta investor relations website. A replay will be available after the event. Azenta is a global leader in life sciences solutions, providing cold-chain sample management and genomic services to the pharmaceutical and biotech industries.
Azenta, Inc. (Nasdaq: AZTA) reported Q1 fiscal 2022 results with revenue of $140 million, an 18% increase year-over-year. Life Sciences Services grew 24%, while Life Sciences Products saw a 10% rise. Diluted EPS from continuing operations was $0.04, with total diluted EPS at $0.58. The company completed the divestiture of its semiconductor automation business for $3 billion, expected to net about $2.4 billion. Guidance for Q2 2022 anticipates revenue between $137 million and $147 million, with non-GAAP earnings per share between $0.07 and $0.15.
Azenta, Inc. (Nasdaq: AZTA) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, presenting at 10:30 a.m. EST. The company, a leader in life sciences solutions, recently rebranded from Brooks Automation, enhancing their focus on critical areas like drug development and clinical research.
Headquartered in Chelmsford, MA, Azenta aims to expedite breakthroughs in healthcare through reliable cold-chain sample management and genomic services. For details, visit www.azenta.com.
Azenta, Inc. (Nasdaq: AZTA) announced the successful completion of the sale of its Semiconductor Solutions Group to Thomas H. Lee Partners for $3.0 billion in cash, with net proceeds expected to be about $2.4 billion. The company allocated approximately $50 million of the sale proceeds to pay off its term loan, while terminating its revolving line of credit. Following this transaction, Azenta will concentrate exclusively on the life sciences industry, planning to utilize the net proceeds for strategic investments.
Azenta, Inc. (Nasdaq: AZTA) will announce its fiscal 2022 Q1 earnings on February 8, 2022, after market close. A conference call to discuss the results will be held the same day at 4:30 p.m. ET. Investors can access the live webcast on Azenta's website, with a replay available on February 9 at 8:30 a.m. ET. The company, a leader in life sciences solutions, has rebranded from Brooks Automation, Inc. and is in the process of selling its Semiconductor Solutions Group business, which is classified as discontinued operations for reporting purposes.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
What does Azenta, Inc. specialize in?
Where is Azenta headquartered?
What are Azenta's main business segments?
What recent financial achievements has Azenta reported?
What notable partnerships has Azenta recently formed?
How does Azenta support the life sciences industry?
What brands are encompassed within Azenta’s portfolio?
What is Azenta’s strategy for shareholder value?
How does Azenta use non-GAAP financial measures?
Who is involved in Azenta’s CEO succession plan?
